UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB








(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2003


( )TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE
ACT OF 1934 For the transition period from                 to
                                          ----------------    ------------------

Commission File Number: 000-31567


                           Rapid Bio Tests Corporation
                           ---------------------------
        (Exact name of small business issuer as specified in its charter)

Nevada                                                               35-0511303
------                                                               ----------
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

                        5409 Ivy Street, Springfield, Oregon 97478
--------------------------------------------------------------------------------
                         (Address of principal executive offices)


                                  (541)686.5989
                                  -------------
                           (Issuer's Telephone Number)



                      APPLICABLE ONLY TO CORPORATE ISSUERS


State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date. As of November 30, 2003 there were
20,584,214 shares of the issuer's $.001 par value common stock issued and
outstanding.



                                       1
<PAGE>



ITEM 1.  FINANCIAL STATEMENTS






                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)

                              FINANCIAL STATEMENTS

                     November 30, 2003 and February 28, 2003





                                       2
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                                 Balance Sheets



                                     ASSETS
                                     ------
<TABLE>
<CAPTION>
<S>                                                                              <C>                    <C>
                                                                              November 30,         February 28,
                                                                                  2003                 2003
                                                                           -----------------     -----------------
                                                                               (Unaudited)

CURRENT ASSETS

   Cash                                                                    $             668     $               -
                                                                           -----------------     -----------------

     Total Current Assets                                                                  -                     -
                                                                           -----------------     -----------------

     TOTAL ASSETS                                                          $             668     $               -
                                                                           =================     =================


                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
                 ----------------------------------------------


CURRENT LIABILITIES

   Accounts payable                                                        $          25,540    $           12,308
   Accounts payable - related parties                                                  2,011                40,941
   Accrued expenses                                                                   38,380                 5,000
   Note payable (Note 3)                                                              13,000                     -
                                                                           -----------------    ------------------

     Total Current Liabilities                                                        78,931                58,249
                                                                           -----------------    ------------------

     Total Liabilities                                                                78,931                58,249
                                                                           -----------------    ------------------

STOCKHOLDERS' EQUITY (DEFICIT)

   Common stock, par value $0.001; authorized
     120,000,000 shares; 20,584,214 and 114,214
     shares issued and outstanding, respectively                                      20,584                   114
   Additional paid-in capital                                                      2,917,638               795,537
   Prepaid services (Note 3)                                                         (30,677)                    -
   Deficit accumulated prior to the development stage                               (989,057)             (989,057)
   Retained earnings (deficit accumulated during the development stage)           (1,996,751)              135,157
                                                                           ------------------    -----------------

     Total Stockholders' Equity (Deficit)                                            (78,263)              (58,249)
                                                                           -----------------    ------------------

     TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY (DEFICIT)                                                     $             668    $                -
                                                                           =================    ==================
</TABLE>



The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                            Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                        From
                                                                                                      Inception
                                                                                                       Of the
                                                                                                     Development
                                                                                                      Stage on
                                                                                                       March 1
                             For the Three Months Ended             For the Nine Months Ended       2001 through
                                      November 30,                        November 30,              November 30,
                           ----------------------------------  ---------------------------------  ----------------
                                  2003             2002              2003             2002              2003
                           ----------------  ----------------  ---------------   ---------------  ----------------
<S>                               <C>              <C>                <C>              <C>               <C>
REVENUES                   $              -  $              -  $             -   $             -  $              -
                           ----------------  ----------------  ---------------   ---------------  ----------------

EXPENSES

     Officer salaries                18,000                 -           42,000                 -            42,000
     Consulting fees                 12,875                 -        2,041,323                 -         2,041,323
     General and administrative      12,911             1,233           47,916             5,610            89,754
                           ----------------  ----------------  ---------------   ---------------  ----------------

Total Expenses                       43,786             1,233        2,131,239             5,610         2,173,077
                           ----------------  ----------------  ---------------   ---------------  ----------------

LOSS FROM OPERATIONS                (43,786)           (1,233)      (2,131,239)           (5,610)       (2,173,077)
                           ----------------  ----------------  ---------------   ---------------  ----------------

OTHER INCOME (EXPENSE)

     Gain on extinguishments of
      debt                                -                 -                -                 -           189,233
     Interest expense                  (130)           (1,832)            (669)           (2,732)          (12,907)
                           ----------------  ----------------  ---------------   ---------------  ----------------

     Total Other Income
     (Expense)                         (130)           (1,832)            (669)           (2,732)          176,326
                           ----------------  ----------------  ---------------   ---------------  ----------------

INCOME (LOSS) BEFORE
 INCOME TAXES                       (43,916)           (3,065)      (2,131,908)           (8,342)       (1,996,751)

     Income taxes                         -                 -                -                 -                 -
                           ----------------  ----------------  ---------------   ---------------  ----------------

NET (LOSS)                 $        (43,916) $         (3,065) $    (2,131,908)  $        (8,342) $     (1,996,751)
                           ================  ================  ===============   ===============  ================

BASIC LOSS PER SHARE:      $          (0.00) $          (0.00) $         (0.12)  $         (0.00)
                           ================  ================  ===============   ===============

WEIGHTED AVERAGE
 NUMBER OF SHARES
 OUTSTANDING                     20,568,170           114,188       17,407,467           114,188
                           ================  ================  ================= ===============
</TABLE>




The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                  Statements of Stockholders' Equity (Deficit)
<TABLE>
<CAPTION>
                                                                                                       Deficit         Deficit
                                                                                                      Accumulated    Accumulated
                                                           Common                   Additional       Prior to the     During the
                                             ---------------------------------        Paid-in         Development    Development
                                                  Shares            Amount            Capital           Stage            Stage
                                             ----------------  ---------------   ----------------  ---------------  ---------------
<S>                                                <C>                <C>               <C>              <C>              <C>
Balance, February 28, 2001                             39,614  $            39   $        563,971  $      (989,057) $             -

Common stock issued in satisfaction
 of debt at $0.123 per share,
 December 17, 2001                                      7,000                7            214,734                -                -

Common stock issued in satisfaction
 of debt at $0.001 per share,
 January 28, 2002                                       4,000                4                996                -                -

Common stock issued for services
 at $0.001 per share,
 February 1, 2002                                      63,600               64             15,836                -                -

Net income for the year ended
 February 28, 2002                                          -                -                  -                -           90,714
                                             ----------------  ---------------   ----------------  ---------------  ---------------

Balance, February 28, 2002                            114,214              114            795,537         (989,057)          90,714

Net income for the year ended
 February 28, 2003                                          -                -                  -                -           44,443
                                             ----------------  ---------------   ----------------  ---------------  ---------------

Balance, February 28, 2003                           114, 214              114            795,537         (989,057)         135,157

Common stock issued for assets at
  predecessor cost of $0.00 per share
  on June 19, 2003 (unaudited)                     15,000,000           15,000            (15,000)               -                -

Common stock issued for consulting
  services at $0.38 per share on
  July 24, 2003 (unaudited)                         5,450,000            5,450          2,065,550                -                -

Assumption and forgiveness of debt
  by related parties (unaudited)                            -                -             61,571                -                -

Common stock issued for cash
  at $0.50 per share on
  November 12, 2003 (unaudited)                        20,000               20              9,980                -                -

Net loss for the nine months ended
 November 30, 2003 (unaudited)                              -                -                  -                -       (2,131,908)
                                             ----------------  ---------------   ----------------   --------------  ----------------
Balance, November 30, 2003 (unaudited)             20,584,214  $        20,584   $      2,917,638   $     (989,057) $    (1,996,751)
                                             ================  ===============   ================   ==============  ================
</TABLE>



The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                            Statements of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                                         From
                                                                                                       Inception
                                                                                                        Of the
                                                                                                      Development
                                                                                                       Stage on
                                                                                                       March 1,
                                                                    For the Nine Months Ended        2001 through
                                                                          November 30,               November 30,
                                                               ----------------------------------  -----------------
                                                                     2003              2002              2003
                                                               -----------------  ---------------  -----------------
<S>                                                                  <C>                <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES

   Net loss                                                    $    (2,131,908)  $       (8,342)   $    (1,996,751)
   Adjustments to reconcile loss from operations
    to net cash used by operating activities:
     Gain on extinguishments of debt                                         -                 -          (189,233)
     Common stock issued for services                                2,040,323                 -         2,056,223
   Changes in assets and liabilities:
     Increase in accrued interest                                          171             1,350            10,518
     Increase in accounts payable and
      accounts payable - related parties                                35,873             6,992            58,702
     Increase in accrued expenses                                       33,209                 -            38,209
                                                               ---------------   ---------------  ----------------

       Net Cash Used by Operating Activities                           (22,332)                -           (22,332)
                                                               ---------------   ---------------  ----------------

CASH FLOWS FROM INVESTING ACTIVITIES                                         -                 -                 -
                                                               ---------------   ---------------  ----------------

CASH FLOWS FROM FINANCING ACTIVITIES

     Proceeds from loan                                                 13,000                 -            13,000
     Common Stock issued for cash                                       10,000                 -            10,000
                                                               ---------------   ---------------  ----------------

       Net cash provided by financing activities                        23,000                 -            23,000
                                                               ---------------   ---------------  ----------------


NET INCREASE (DECREASE) IN CASH                                            668                 -               668

CASH AT BEGINNING OF PERIOD                                                  -                 -                 -
                                                               ---------------   ---------------  ----------------

CASH AT END OF PERIOD                                          $           668   $             -  $            668
                                                               ===============   ===============  ================
</TABLE>




The accompanying notes are an integral part of these financial statements.

                                       6
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                      Statements of Cash Flows (Continued)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                       From
                                                                                                     Inception
                                                                                                      Of the
                                                                                                    Development
                                                                                                     Stage on
                                                                                                      March 1,
                                                                    For the Nine Months Ended      2001 through
                                                                          November 30,              November 30,
                                                               ---------------------------------- ----------------
                                                                    2003              2002             2003
                                                               ---------------   ---------------- ----------------
<S>                                                                 <C>                <C>              <C>
SUPPLEMENTAL CASH FLOW INFORMATION:

   Cash paid for:

     Interest                                                  $             -   $             -  $              -
     Income taxes                                              $             -   $             -  $              -

NON-CASH FINANCING AND INVESTING ACTIVITIES:

     Common stock issued in lieu of debt                       $             -   $             -  $        215,741
     Common stock issued for services                          $     2,040,323   $             -  $      2,056,223
</TABLE>








The accompanying notes are an integral part of these financial statements.

                                       7
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                        Notes to the Financial Statements
                     November 30, 2003 and February 28, 2003


   NOTE 1 -  BASIS OF FINANCIAL STATEMENT PRESENTATION

             The accompanying unaudited financial statements have been prepared
             by the Company pursuant to the rules and regulations of the
             Securities and Exchange Commission. Certain information and
             footnote disclosures normally included in financial statements
             prepared in accordance with accounting principles generally
             accepted in the United States of America have been condensed or
             omitted in accordance with such rules and regulations. The
             information furnished in the interim financial statements include
             normal recurring adjustments and reflects all adjustments, which,
             in the opinion of management, are necessary for a fair presentation
             of such financial statements. Although management believes the
             disclosures and information presented are adequate to make the
             information not misleading, it is suggested that these interim
             financial statements be read in conjunction with the Company's most
             recent audited financial statements and notes thereto included in
             its February 28, 2003 Annual Report on Form 10-KSB. Operating
             results for the nine months ended November 30, 2003 are not
             necessarily indicative of the results that can be expected for the
             year ending February 28, 2004.

   NOTE 2 -   GOING CONCERN

              The Company's financial statements are prepared using accounting
              principles generally accepted in the United States of America
              applicable to a going concern which contemplates the realization
              of assets and liquidation of liabilities in the normal course of
              business. The Company currently has minimal operations and has
              incurred significant losses which have resulted in an accumulated
              deficit of $2,985,808 at November 30, 2003 which raises
              substantial doubt about the Company's ability to continue as a
              going concern. The accompanying financial statements do not
              include any adjustments relating to the recoverability and
              classification of asset carrying amounts or the amount and
              classification of liabilities that might result from the outcome
              of this uncertainty.

              It is the intent of management to continue to work to develop
              rapid diagnostic testing technology platforms that will be used
              for the development and manufacturing of an array of rapid
              diagnostic tests. The initial tests that the Company is proposing
              to develop include; West Nile Virus, Hepatitis B, HIV 1 and 2,
              Tuberculosis, Bubonic Plague, and the four strains of Malaria.
              Until this occurs, the Company's management intends to provide the
              Company with sufficient working capital to cover its operating
              expenses. However, there is no assurance that the Company's plans
              will be successful or that the Company's management will continue
              to provide sufficient capital to cover the operating expenses of
              the Company.

   NOTE 3 -   MATERIAL EVENTS

              Related Party Transactions
              ---------------------------

              During the nine months ended November 30, 2003, the former
              officers and directors of the Company forgave the $61,571 of the
              Company's debt. This amount has been recorded as a contribution of
              capital.


                                       8
<PAGE>


                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                        Notes to the Financial Statements
                     November 30, 2003 and February 28, 2003


   NOTE 3 -   MATERIAL EVENTS (Continued)

              Reverse Stock Split
              -------------------

              On April 25, 2003, the Company consummated a reverse split of its
              issued and outstanding common stock on a 1-for-250 basis. As a
              result of the stock split, each two hundred fifty (250) shares of
              the Company's issued and outstanding common stock was decreased to
              one (1) fully paid and nonassessable share of common stock, $0.001
              par value per share. Fractional shares were rounded upward. The
              reverse stock split reduced the number of shares of common stock
              outstanding from 28,546,972 shares as of April 24, 2003, to
              approximately 114,214 shares. The par value of the common stock
              did not change. The shares of common stock have been retroactively
              restated in the financial statements for the reverse split for all
              periods presented.

              Name Change
              -----------

              On June 12, 2003, the Company changed its corporate name from
              Vitatonics Corp. to Rapid Bio Tests Corporation. The name change
              became effective with the filing of a Certificate of Amendment to
              the Company's Articles of Incorporation with the Nevada Secretary
              of State. The Company changed its name to reflect a change in its
              business focus.

              Increase in Authorized Common Stock
              -----------------------------------

              On June 12, 2003, the Company filed an Amendment to its Articles
              of Incorporation, which increased its authorized number of shares
              of its $0.001 par value common stock from 50,000,000 to
              120,000,000.

              The name change, reverse split and increase in authorized shares
              of common stock were approved on April 25, 2003, by unanimous
              approval of the Company's Board of Directors. In addition, on
              April 25, 2003, shareholders holding a majority of the Company's
              outstanding common stock approved those actions by written consent
              in lieu of a meeting in accordance with the relevant sections of
              the Nevada Revised Statutes.

              Change of Symbol and CUSIP Number
              ---------------------------------

              Concurrent with the above actions, the Company was issued a new
              symbol and CUSIP Number. The Company's symbol changed from "VITN"
              to "RBIO," and its CUSIP Number has changed from 928488-10-5 to
              753339-10-0.

              Resignations
              ------------

              On June 16, 2003, the following occurred: (i) Daniel McCormick
              resigned as the President and director of the Company; (ii) George
              Farquhar (effective August 23, 2003) resigned as the Secretary,
              Chief Financial Officer and director of the Company; and (iii)
              Dennis McCormick resigned as director of the Company. None of the
              resignations were the result of any disagreement with the Company
              on any matter relating to the Company's operations, policies or
              practices.


                                       9
<PAGE>


                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                        Notes to the Financial Statements
                     November 30, 2003 and February 28, 2003


NOTE 3 -      MATERIAL EVENTS (Continued)

              Appointment of New Officers and Directors
              -----------------------------------------

              On June 16, 2003, the following occurred: (i) Geoffrey V.F.
              Seaman, Ph.D. was appointed as President, Chief Executive Officer
              and a director of the Company; (ii) Paul Hemmes, Ph.D. was
              appointed as Secretary, Treasurer, Chief Financial Officer and a
              director of the Company; and (iii) David H. Regan, M.D. was
              appointed as Vice President of Medical Affairs and a director of
              the Company.

              Stock Issuances
              ---------------

              On June 16, 2003, Dr. Seaman, Hemmes and Regan executed Employment
              and Asset Purchase Agreements (the "Agreements"). The purpose of
              the Agreements was to retain their management and technical
              services, including their intellectual property necessary to
              develop the Company's proposed medical testing products. Pursuant
              to the Agreements, the Company issued 9,000,000 shares of its
              common stock to Dr. Seaman, 4,000,000 shares of its common stock
              to Dr. Hemmes, and 2,000,000 shares of its common stock to Dr.
              Regan in exchange for certain intellectual property necessary to
              develop the Company's proposed products and processes. The value
              of the shares issued in exchange for the intellectual property
              were valued at $0.00 which represented predecessor cost.

              With the assistance of its new management and the intellectual
              property transferred under the Agreements, the Company intends to
              develop, manufacture and market a series of diagnostic tests that
              can be used to detect a variety of human diseases and conditions,
              and which have utility in a variety of veterinary and agricultural
              products. The Company believes that rapid, sensitive, accurate and
              reliable diagnostic tests are necessary to respond to epidemics,
              bio-terrorism attacks and simply to cut the current high cost of
              diagnostics for general health care.

              On July 24, 2003, the Company issued 5,450,000 shares of common
              stock for services to nine (9) individuals valued at the closing
              price on the date of issue or $0.38 per share. Total consideration
              value of the issuances was $2,071,000. The Company expensed
              $2,028,448 of the share value and allocated $42,552 to prepaid
              services which will be expensed ratably over a 12 month period.

              On November 12, 2003, the Company issued 20,000 shares of common
              stock for cash to one individual at $0.50 per share.

              Note Payable
              ------------

              The Company received $13,000 from unrelated third parties during
              the quarter ended November 30, 2003. No terms on the notes have
              been established yet.


                                       10
<PAGE>


    NOTE 3 -  MATERIAL EVENTS (Continued)

              2003 Stock Option Plan
              ----------------------

              On August 26, 2003, the Company adopted and approved the 2003
              stock option plan. The plan is intended to help attract and retain
              the services of persons now performing services for the Company.
              The shares purchased under this plan cannot exceed in aggregate,
              30% of the issued and outstanding common stock of the Company. The
              exercise price for each issuance will be determined by the
              Company.


              Stock Options
              -------------

              On September 9, 2003, the Company approved the issuance of 100,000
              options as payment for services. The options are exercisable at
              $0.65 per share. These options were subsequently cancelled by the
              Board of Directors.






                                       11
<PAGE>


ITEM 2.  PLAN OF OPERATION

THIS FOLLOWING INFORMATION SPECIFIES CERTAIN FORWARD-LOOKING STATEMENTS OF
MANAGEMENT OF THE COMPANY. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT
ESTIMATE THE HAPPENING OF FUTURE EVENTS AND ARE NOT BASED ON HISTORICAL FACT.
FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING
TERMINOLOGY, SUCH AS "MAY", "SHALL", "COULD", "EXPECT", "ESTIMATE",
"ANTICIPATE", "PREDICT", "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", OR
SIMILAR TERMS, VARIATIONS OF THOSE TERMS OR THE NEGATIVE OF THOSE TERMS. THE
FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION HAVE BEEN
COMPILED BY OUR MANAGEMENT ON THE BASIS OF ASSUMPTIONS MADE BY MANAGEMENT AND
CONSIDERED BY MANAGEMENT TO BE REASONABLE. OUR FUTURE OPERATING RESULTS,
HOWEVER, ARE IMPOSSIBLE TO PREDICT AND NO REPRESENTATION, GUARANTY, OR WARRANTY
IS TO BE INFERRED FROM THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE FORWARD-LOOKING STATEMENTS SPECIFIED IN
THE FOLLOWING INFORMATION REPRESENT ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT
TO UNCERTAINTY AS TO POSSIBLE CHANGES IN ECONOMIC, LEGISLATIVE, INDUSTRY, AND
OTHER CIRCUMSTANCES. AS A RESULT, THE IDENTIFICATION AND INTERPRETATION OF DATA
AND OTHER INFORMATION AND THEIR USE IN DEVELOPING AND SELECTING ASSUMPTIONS FROM
AND AMONG REASONABLE ALTERNATIVES REQUIRE THE EXERCISE OF JUDGMENT. TO THE
EXTENT THAT THE ASSUMED EVENTS DO NOT OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY
FROM ANTICIPATED OR PROJECTED RESULTS, AND, ACCORDINGLY, NO OPINION IS EXPRESSED
ON THE ACHIEVABILITY OF THOSE FORWARD-LOOKING STATEMENTS. WE CANNOT GUARANTY
THAT ANY OF THE ASSUMPTIONS RELATING TO THE FORWARD-LOOKING STATEMENTS SPECIFIED
IN THE FOLLOWING INFORMATION ARE ACCURATE, AND WE ASSUME NO OBLIGATION TO UPDATE
ANY SUCH FORWARD-LOOKING STATEMENTS.

CRITICAL ACCOUNTING POLICY AND ESTIMATES. Our Management's Discussion and
Analysis of Financial Condition and Results of Operations section discusses our
financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States of America. The preparation
of these financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. On an on-going basis, management evaluates
its estimates and judgments, including those related to revenue recognition,
accrued expenses, financing operations, and contingencies and litigation.
Management bases its estimates and judgments on historical experience and on
various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different
assumptions or conditions. The most significant accounting estimates inherent in
the preparation of our financial statements include estimates as to the
appropriate carrying value of certain assets and liabilities which are not
readily apparent from other sources. These accounting policies are described at
relevant sections in this discussion and analysis and in the notes to the
financial statements included in our Quarterly Report on Form 10-QSB for the
period ended November 30, 2003.

OUR BUSINESS. With the assistance of our management team which joined us last
year, we intend to develop, manufacture and market a series of rapid, sensitive,
accurate and reliable diagnostic tests that can be used to detect a variety of
human diseases and conditions, and which have utility in a variety of veterinary
and agricultural products. We believe that diagnostic tests are necessary to
respond to epidemics, bio-terrorism attacks and simply to cut the current high
cost of diagnostics for general health care.

Our current management has examined a wide range of current technologies used
for rapid identification of microorganisms and toxic agents, but believes that
cutting edge and high tech approaches are unproven on a large scale and do not
meet the needs of today's environment. For these reasons, we will focus our
efforts on established technology. We propose to develop a panel of rapid,
accurate, robust and easy to perform tests for field assays and point-of-care
testing. We also propose to develop a product line of tests for the rapid and
definitive detection of infectious diseases including bacterial and viral
pathogens, as well as toxins, which our management believes can be met by rapid
latex agglutination slide tests for the primary on-site identification. We
believe that such tests are simple, easy to manufacture, inexpensive and do not
require instrumentation or electricity, nor are highly trained personnel
necessary to read the test results.


                                       12
<PAGE>

We believe that an appropriate combination of the technology inventions,
identification of ideal target markets, coupled with the basic capabilities of
the principals will enable us to achieve our objectives and rapidly reduce the
latex technology platforms to practice, allowing us to proceed to
commercialization and sale of our products.

LIQUIDITY AND CAPITAL RESOURCES. We had $668 in cash as at November 30, 2003,
and $668 in total assets as at November 30, 2003. Our total current liabilities
were $78,931 at November 30, 2003, which was represented by accounts payable of
$25,540, along with $2,011 in accounts payable to related parties, $38,380 in
accrued expenses and $13,000 represented by a note payable. At November 30,
2003, our liabilities exceeded our assets by $78,263.

FOR THE THREE MONTH PERIOD ENDED NOVEMBER 30, 2003.

RESULTS OF OPERATIONS.

REVENUES. From inception of the development stage on March 1, 2001 through
November 30, 2003, we have not realized any revenues. We hope to generate
revenues in the next twelve months by actively pursuing our newly adopted
business plan and by the eventual sale of our planned line of diagnostic testing
products. However, we cannot guarantee that our products will be ready for sale
or that we will earn any revenues within the next twelve months.

OPERATING EXPENSES. For the three months ended November 30, 2003, our total
operating expenses were $43,786 compared to total expenses of $1,233 for the
corresponding period in 2002. The expenses for the three months ended November
30, 2003 was represented by $18,000 in officer salaries, $12,875 in consulting
fees and $12,911 in general and administrative expenses. This is in comparison
to the same period ending November 30, 2002, where we had operating expenses of
$1,233 which was represented solely by general and administrative expenses. The
large increase in operating expenses is due to incurring officer salaries and
consulting expenses, incurred as a result of operating under our new management
and business plan.

For the three months ending November 30, 2003, we also had an interest expense
of $130. Therefore our net loss was $43,916 for the three months ended November
30, 2003. This is in comparison to $1,832 in interest expenses for the three
months ending November 30, 2002. For the corresponding period ending in 2002,
our net loss was $3,065.

March 1, 2001 through November 30, 2003 was $2,173,077. However, our cumulative
net loss from inception of the development stage on March 1, 2001 through
November 30, 2003 was $1,996,751 which was due to a gain of $189,233 which we
recognized on extinguishments of debt less interest expense of $12,907.

FOR THE NINE MONTH PERIOD ENDED NOVEMBER 30, 2003.
--------------------------------------------------

RESULTS OF OPERATIONS.

REVENUES. For the nine months ended November 30, 2003, we have not realized any
revenues.

OPERATING EXPENSES. For the nine months ended November 30, 2003, our total
operating expenses were $2,131,239 compared to total expenses of $5,610 for the
corresponding period in 2002. The expenses for the nine months ended November
30, 2003 was represented by $42,000 in officer salaries, $2,041,323 in
consulting fees and $47,916 in general and administrative expenses. This is in
comparison to the same period ending November 31, 2002, where we had operating
expenses of $5,610 which was represented solely by general and administrative
expenses. The large increase in operating expenses is due to incurring officer
salaries and consulting expenses, incurred as a result of operating under our
new management and business plan.

                                       13
<PAGE>

For the nine months ending November 30, 2003, we also had an interest expense of
$669. Therefore our net loss was $2,131,908 for the nine months ended November
30, 2003. This is in comparison to $2,732 in interest expenses for the nine
months ending August 31, 2002, making our net loss for the corresponding period
ending in 2002 a total of $8,342.

OUR PLAN OF OPERATION FOR THE NEXT TWELVE MONTHS. As of November 30, 2003, we
had no cash resources. We have not yet generated any revenues from operations.
We plan on raising additional operating funds through the sale of our common
stock. If we are not able to raise additional funds, we may arrange for loans or
other borrowings. Our forecast of the period of time through which our financial
resources will be adequate to support our operations is a forward-looking
statement that involves risks and uncertainties, and actual results could vary
as a result of a number of factors. There is no guarantee that we will be able
to sell shares of our common stock or that we will be able to arrange for
borrowings on acceptable terms if at all.

We have been developing a test that our management believes will be able to
detect the presence of Bovine Spongiform Encephalopathy or Mad Cow Disease
(BSE). While the test is not currently in production or ready for market, we
believe that our test to detect BSE is nearing final development, after which we
plan to begin testing a prototype. Such a test would then be submitted to the
FDA, whose approval would be required before the test could be commercially
marketed and put in use. Our management estimates that the costs of development
work for the completion of one rapid sensitive test on live animals for
indicators of BSE, plus initial work on ways to block the disease would total
approximately $700,000. While we do not currently have the financial resources
to complete this development, we plan to seek such funding if our feasibility
tests indicate the viability for commercial development and production of the
diagnostic test. Our management team has an extensive track record in developing
similar diagnostic tests for neurological problems, which we believe will
facilitate the launch of our proposed BSE tests and treatments.

Our plan of operation is materially dependent on our ability to continue the
development of our proposed line of diagnostic tests and raise additional
capital to market our products. Within the next twelve months, we hope to begin
the manufacturing and marketing of our products. We must also enter into
arrangements with manufacturers to manufacture our planned product line.
Finally, we must raise additional working capital either through the sale of our
common stock or through loans. There is no guarantee that we will be able to
raise additional capital through the sale of our common stock. Moreover, there
is no guarantee that we will be able to arrange for loans on favorable terms, or
at all.

Our inability to access the capital markets or obtain acceptable financing could
harm our results of operations and financial condition. To the extent that
additional capital is raised through the sale of equity or equity-related
securities, the issuance of such securities could result in dilution of our
stockholders. We cannot guaranty that additional funding will be available on
favorable terms. If adequate funds are not available within the next 12 months,
we may be required to limit our proposed diagnostic testing development
activities or to obtain funds through entering into arrangements with
collaborative partners. If adequate funds are not available, we believe that our
officers and directors will contribute funds to pay for our expenses. Our belief
that our officers and directors will pay our expenses is based on the fact that
our officers and directors collectively own 15,000,000 shares of our common
stock, which equals approximately 72.9% of our total issued and outstanding
common stock. We believe that our officers and directors will continue to pay
our expenses as long as they maintain their ownership of our common stock. If
our officers and directors loan us operating capital, we will either execute
promissory notes to repay the funds or issue stock to those officers and
directors. We have not formulated specific repayment terms. We will negotiate
the specific repayment terms and whether repayment will be in the form of stock
when, and if, funds are advanced by any of our officers and directors.

Over the next twelve months, we plan to continue with our ongoing research and
development activities to develop our proposed line of diagnostic tests.
Specifically, we are currently studying the development of rapid diagnostic
tests for Bovine Spongiform Encephalopathy, Hepatitis B, West Nile Virus and a
test to establish successful vaccinations for small pox. Over the next twelve
months, we do not anticipate that we will purchase or sell any significant
equipment, but rather, utilize the facilities and equipment our scientific team
currently has access to. In the event that we are able to begin manufacturing
operations, then we may need to hire additional employees or independent
contractors.

                                       14
<PAGE>

ITEM 3. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. We maintain controls and
procedures designed to ensure that information required to be disclosed in the
reports that we file or submit under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission. Based upon
their evaluation of those controls and procedures performed as of November 30,
2003, our chief executive officer and the principal financial officer concluded
that our disclosure controls and procedures were adequate.

(b) Changes in internal controls. There were no significant changes in our
internal controls or in other factors that could significantly affect these
controls subsequent to the date of the evaluation of those controls by the chief
executive officer and principal financial officer.

                          PART II -- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
--------------------------

None.

ITEM 2. CHANGES IN SECURITIES.
------------------------------

None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
----------------------------------------

None.

ITEM 4.  SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
----------------------------------------------------------

None.

ITEM 5.  OTHER INFORMATION
--------------------------

Subsequent to the reporting period covered by the form on this report, on
January 12, 2004 we filed a report on form 8-K containing Item 5 - Other events,
attaching our press release dated January 9, 2004 announcing that we have been
conducting feasibility studies related to a test for Bovine Spongiform
Encephalopathy, commonly know n as Mad Cow Disease. A copy of the press release
was attached to that Form 8-K as Exhibit 99.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K
-----------------------------------------

(a) Exhibits.

         31. Rule 13a-14(a)/15d-14(a) Certifications.

         32. Section 1350 Certifications.

(b) Reports on Form 8-K

On November 17, 2003, we filed a report on Form 8-K to report the following
under Item 6. - Resignations of Registrant's Directors to report that on
November 8, 2003, Thomas F. Zimmerman III tendered his resignation as our
President and one of our directors. The resignation is not the result of any
disagreement with the registrant on any matter relating our operations, policies
or practices. A copy of Dr. Zimmerman's resignation was filed as Exhibit 17.1 to
this Form 8-K.


                                       15
<PAGE>

                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

                                             Rapid Bio Tests Corporation,
                                             a Nevada corporation



January 14, 2004           By:        /s/    Geoffrey V.F. Seaman
                                      ------------------------------------------
                                             Geoffrey V.F. Seaman
                                      Its:   Chief Executive Officer, Director